Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 02 2019
Historique:
received: 20 08 2018
accepted: 12 12 2018
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 13 11 2020
Statut: epublish

Résumé

Accurate diagnosis of histological type is important for therapy selection in lung cancer. Immunohistochemical (IHC) and histochemical stains are often used to complement morphology for definite diagnosis and are incorporated in the WHO classification. Our main aim was to compare different mucin stains and assess their value in relation to common IHC analyses in lung cancer diagnostics. Using tissue microarrays from 657 surgically treated primary lung cancers, we evaluated the mucin stains periodic acid-Schiff with diastase (PASD), alcian blue-periodic acid-Schiff (ABPAS) and mucicarmine, and compared with the IHC markers p40, p63, cytokeratin 5, thyroid transcription factor 1 (TTF-1), napsin A and cytokeratin 7. Ten or more cytoplasmic mucin inclusions in a tissue microarray core were seen in 51%, 48% and 31% of the 416 adenocarcinomas and 3%, 4% and 0.5% of the 194 squamous cell carcinomas with PASD, ABPAS and mucicarmine, respectively. Diagnostic pitfalls, such as entrapped benign epithelium, apoptotic/necrotic cells and glycogen, partly differed for the mucin stains. TTF-1 and napsin A IHC stainings had similar specificity but better sensitivity for adenocarcinoma than the mucin stains, but addition of PASD or ABPAS identified more tumors as adenocarcinomas (n = 8 and n = 10, respectively) than napsin A (n = 1) in cases with solid growth that were negative for TTF-1 and p40. We conclude that PASD and ABPAS have similar diagnostic performance and that these markers are of value in poorly differentiated cases. However, morphology and TTF-1 and p40 IHC staining is sufficient for correct diagnosis in most non-small cell lung cancers.

Identifiants

pubmed: 30718697
doi: 10.1038/s41598-018-37722-0
pii: 10.1038/s41598-018-37722-0
pmc: PMC6362145
doi:

Substances chimiques

Biomarkers, Tumor 0
Mucins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319

Références

Hum Pathol. 2000 Aug;31(8):980-7
pubmed: 10987260
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
Histopathology. 2004 Aug;45(2):125-34
pubmed: 15279630
Oncologist. 2009 Mar;14(3):253-63
pubmed: 19221167
J Thorac Oncol. 2010 Apr;5(4):436-41
pubmed: 20068475
J Thorac Oncol. 2010 Apr;5(4):442-7
pubmed: 20195168
Am J Surg Pathol. 2010 Dec;34(12):1805-11
pubmed: 21107086
Histopathology. 2012 Dec;61(6):1017-25
pubmed: 22882703
Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):292-7
pubmed: 23060301
Indian J Med Paediatr Oncol. 2013 Oct;34(4):229-33
pubmed: 24604948
Hum Pathol. 1989 Sep;20(9):845-9
pubmed: 2476374
J Nat Sci Biol Med. 2014 Jul;5(2):404-8
pubmed: 25097424
J Thorac Oncol. 2016 Jun;11(6):862-72
pubmed: 26872818
Am J Pathol. 1988 Oct;133(1):30-8
pubmed: 2845790
J Thorac Oncol. 2018 Mar;13(3):323-358
pubmed: 29396253
Am J Clin Pathol. 2018 Oct 24;150(6):533-544
pubmed: 30169783
Hum Pathol. 2018 Oct 30;:null
pubmed: 30389437
Br J Dis Chest. 1975 Apr;69(2):137-43
pubmed: 49191

Auteurs

Patrick Micke (P)

Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85, Uppsala, Sweden.

Johan Botling (J)

Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85, Uppsala, Sweden.

Johanna Sofia Margareta Mattsson (JSM)

Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85, Uppsala, Sweden.

Maria Planck (M)

Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 00, Lund, Sweden.
Department of Respiratory medicine and Allergology, Skåne University Hospital, SE-221 85, Lund, Sweden.

Lena Tran (L)

Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, SE-221 85, Lund, Sweden.

Halla Vidarsdottir (H)

Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 00, Lund, Sweden.
Department of Surgery, Helsingborg Hospital, SE-251 87, Helsingborg, Sweden.

Björn Nodin (B)

Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 00, Lund, Sweden.

Karin Jirström (K)

Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 00, Lund, Sweden.
Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, SE-221 85, Lund, Sweden.

Hans Brunnström (H)

Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 00, Lund, Sweden. hans.brunnstrom@med.lu.se.
Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, SE-221 85, Lund, Sweden. hans.brunnstrom@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH